Amyloid-beta peptide-metal ion complex (Aβ-metal complex) (Aβ-metal complex)

The interaction between copper (Cu2+) and zinc (Zn2+) ions and the amyloid-beta (Aβ) peptide is a critical factor in the pathogenesis of Alzheimer's disease (Bush, 2003, Trends in Neurosciences). These metal ions bind primarily to the N-terminal histidine residues (His6, His13, and His14) of Aβ, significantly influencing the peptide's folding, aggregation kinetics, and toxicity (Fallon et al., 2014, Coordination Chemistry Reviews). Zinc ions typically promote the rapid precipitation of Aβ into amorphous aggregates, while copper ions can facilitate the formation of neurotoxic oligomers and catalyze the production of reactive oxygen species (ROS) through redox cycling (Barnham & Bush, 2014, Chemical Society Reviews). Therapeutic strategies targeting these complexes, known as metal-protein attenuating compounds (MPACs) like PBT2, aim to redistribute metal ions and inhibit the formation of toxic Aβ species (Adlard et al., 2008, Neuron). By disrupting the metal-Aβ interaction, these drugs seek to reduce oxidative damage and promote the clearance of amyloid deposits in the brain (Prana Biotechnology, 2014). This approach represents a unique strategy in neurotherapeutics, focusing on the bio-inorganic chemistry of the neurodegenerative environment.

Other names

Copper-amyloid-beta complexZinc-amyloid-beta complexMetal-Aβ complexAβ-Cu/Zn complexMetal-bound amyloid-beta

Metal-protein attenuation and competitive chelation to disrupt amyloid-beta aggregation and neutralize metal-induced reactive oxygen species production.